Question | Discussion | References | CME Credit

Case 1: References

  1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338: 853-60.
    [The following link will open in a new window. PubMed Abstract]
  2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services.  January 29, 2008; 1-128. Available at:
    [The following link will open in a new window. AIDSinfo - Accessed April 4, 2008]
  3. Hammer SM, EronJJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555-70.
    [The following link will open in a new window. PubMed Abstract]
  4. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet. 1998:51:543-9.
    [The following link will open in a new window. PubMed Abstract]
  5. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997:337:725-33.
    [The following link will open in a new window. PubMed Abstract]
  6. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-70.
    [The following link will open in a new window. PubMed Abstract]
  7. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-54.
    [The following link will open in a new window. PubMed Abstract]
  8. Phair JP, Mellors JW, Detels R, Margolick JB, Munoz A. Virologic and immunologic values allowing safe deferral of antiretroviral therapy. AIDS. 2002;16:2455-9.
    [The following link will open in a new window. PubMed Abstract]
  9. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-29.
    [The following link will open in a new window. PubMed Abstract]
  10. May M, Sterne JA, Sabin C, et al; Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21:1185-97.
    [The following link will open in a new window. PubMed Abstract]
  11. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JS. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568-77.
    [The following link will open in a new window. PubMed Abstract]
  12. Sterling TR, Chaisson RE, Keruly J, Moore RD. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J Infect Dis. 2003;188:1659-65.
    [The following link will open in a new window. PubMed Abstract]
  13. Sterling TR, Chaisson RE, Moore RD. Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity. Clin Infect Dis. 2003;36:812-5.
    [The following link will open in a new window. PubMed Abstract]
  14. Opravil M, Ledergerber B, Furrer H, et al. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6)/l. AIDS. 2002;16:1371-81.
    [The following link will open in a new window. PubMed Abstract]
  15. Kaplan JE, Hanson DL, Cohn DL. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL. Clin Infect Dis. 2003;37:951-8.
    [The following link will open in a new window. PubMed Abstract]

[Back to Case 1 Question | Back to Discussion]

CME Credit | Back to Top